KLK12
Kallikrein-12
Also known as: KLK-L5, KLK12_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9UKR0
- Gene
- KLK12
- Ensembl
- ENSG00000186474
- Chromosome
- 19
- Canonical length
- 248 aa
- Protein class
- Enzymes, Predicted secreted proteins
- Secretome location
- Secreted in other tissues
OverviewNCBI Gene
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Alternate splicing of this gene results in three transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
248 residues, UniProt reviewed canonical sequence.
>Q9UKR0|KLK12
1 MGLSIFLLLC VLGLSQAATP KIFNGTECGR NSQPWQVGLF EGTSLRCGGV LIDHRWVLTA
61 AHCSGSRYWV RLGEHSLSQL DWTEQIRHSG FSVTHPGYLG ASTSHEHDLR LLRLRLPVRV
121 TSSVQPLPLP NDCATAGTEC HVSGWGITNH PRNPFPDLLQ CLNLSIVSHA TCHGVYPGRI
181 TSNMVCAGGV PGQDACQGDS GGPLVCGGVL QGLVSWGSVG PCGQDGIPGV YTYICKYVDW
241 IRMIMRNNLocalizationUniProt · AlphaFold · HPA
Whether an antibody against KLK12 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 78 nTPM
Expression across tissuesHPA
Tissue
- esophagus: 78 nTPM
- vagina: 35 nTPM
- salivary gland: 34 nTPM
- cervix: 25 nTPM
- tonsil: 9.2 nTPM
- small intestine: 5.2 nTPM
Single-cell type
- esophageal apical cells: 5,677 nCPM
- esophageal suprabasal cells: 305 nCPM
- suprabasal keratinocytes: 120 nCPM
- submucosal glandular cells: 78 nCPM
- paneth cells: 66 nCPM
- late spermatids: 50 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- choroid plexus: 4.8 nTPM
- hippocampal formation: 0.2 nTPM
- pons: 0.2 nTPM
- cerebellum: 0.1 nTPM
- medulla oblongata: 0.1 nTPM
- thalamus: 0.1 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.36
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.33
- DepMap mean gene effect
- 0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads KLK12 as an antibody target. Whether an autoantibody or antibody against KLK12 could matter depends on whether native KLK12 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
KLK12 is annotated as secreted, so native KLK12 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label KLK12 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...